Loading
JPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥29.00
¥0.00 · 0.00%
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Latest quote
¥29.00
¥0.00 · 0.00%
Regular session · JST · Market data may be delayed.
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Day range
Current ¥29.00
52-week range
Current ¥29.00
Regular session · JST · Market data may be delayed.
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Day range
Current ¥29.00
52-week range
Current ¥29.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 429M JPY | 316M JPY | 617M JPY | 1.09B JPY | 559M JPY |
| Cost of goods sold | 258M JPY | 326M JPY | 780M JPY | 964M JPY | 680M JPY |
| Gross profit | 171M JPY | −10M JPY | −163M JPY | 128M JPY | −121M JPY |
| Research and development | 430M JPY | 414M JPY | 403M JPY | 883M JPY | 845M JPY |
| Selling, general, and administrative | 637M JPY | 567M JPY | 573M JPY | 974M JPY | 1.45B JPY |
| Operating expenses | 1.03B JPY | 981M JPY | 976M JPY | 1.86B JPY | 2.3B JPY |
| Interest income | 1M JPY | — | 10M JPY | — | — |
| Interest expense | 14M JPY | 5M JPY | — | 18M JPY | 23M JPY |
| Depreciation and amortization | 37M JPY | 195M JPY | 500M JPY | 534M JPY | 495M JPY |
| Operating income | −859M JPY | −991M JPY | −1.14B JPY | −1.73B JPY | −2.42B JPY |
| Net income | −876M JPY | −1.94B JPY | −1.11B JPY | −2.55B JPY | −2.48B JPY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
